Splenic Artery Ligation and Portocaval Shunt in Small-for-size Syndrome

Hemodynamic Modulations to Ameliorate Sinusoidal Injuries After Extended Liver Resections: the Role of Splenic Artery Ligation and Porto-caval Shunt in a Series of Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05459883

Acronym

splen ligation

Enrollment

Registered

2022-07-15

Start date

2017-01-01

Completion date

2021-12-31

Last updated

2022-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatectomy, Ischemia, Ligation, Liver Regeneration, Portal Vein, Reperfusion Injury, Small-For-Size Liver Syndrome, Splenic Artery

Keywords

small-for-size liver syndrome, ligation, splenic artery, hepatectomy, liver regeneration

Brief summary

Our study aimed at assessing the changes of portal vein pressure, portal vein flow and hepatic arterial flow (HAF) in liver remnants ≤ 30% of the standard liver volume by reducing portal vein overflow via ligation of the splenic artery.

Detailed description

It has been reported that prevention of acute portal overpressure in small-for-size liver grafts leads to better postoperative outcomes. Accordingly, we aimed to investigate the feasibility of the technique of splenic artery ligation in a case series of patients subjected to major liver resections with evidence of small-for-size syndrome and whether the maneuver results in reduction of portal venous pressure and flow.

Interventions

PROCEDUREsplenic artery ligation

We identified portal hyperperfusion as a cause of potential small-for-size liver remnant dysfunction and we applied splenic artery ligation as a technically simple procedure to manage the situation

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Adult patients * American Society of Anesthesiologists (ASA) distribution I to III * Patients scheduled for major liver resection (≥4 segments)

Exclusion criteria

* patients with extrahepatic disease * patients with metastatic liver tumors

Design outcomes

Primary

Measure	Time frame	Description
portal vein pressure	through the operation, an average period of two hours	change of portal vein pressure from before liver resection to after reperfusion of the liver remnant
portal vein flow	through the operation, an average period of two hours	change of portal vein flow from before liver resection to after reperfusion of the liver remnant
hepatic artery flow	through the operation, an average period of two hours	change of hepatic artery flow from before liver resection to after reperfusion of the liver remnant

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026